Evolution in upfront treatment strategies for metastatic RCC.,Nature Reviews Urology

当前位置： X-MOL 学术 › Nat. Rev. Urol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Evolution in upfront treatment strategies for metastatic RCC.
Nature Reviews Urology ( IF 12.1 ) Pub Date : 2020-01-07 , DOI: 10.1038/s41585-019-0271-6
Dominick Bossé ₁ , Michael Ong ₁

Affiliation

The treatment paradigm for treatment-naive metastatic clear cell renal cell carcinoma continued to evolve in 2019 as three phase III randomized controlled trials were reported comparing sunitinib with combination immune checkpoint inhibitors and VEGF-targeted therapy. Pembrolizumab plus axitinib and avelumab plus axitinib became new treatment options for untreated patients, irrespective of risk group or PD-L1 expression.

中文翻译：